The domestic copyright of Paclitaxel anticancer drugs has shifted one after another. Samyang Biopharmaceuticals' Genexol, the No. 1 item in the market, will be jointly sold by HK inno.N instead of Boryung. Boryung will jointly sell BMS Taxol, the original product, for the first time in seven years instead of Genexol. The annual sales of the two products are worth 21 billion won for Genexol and 9 billion won for Taxol. According to the pharmaceutical industry on the 16th, Boryung will jointly sell BMS Taxol in Korea from January 1 this year. Taxol is a cytotoxic anticancer drug composed of Paclitaxel. It is widely used for various cancers such as ovarian cancer, breast cancer, lung cancer, and gastric cancer. It has be